Plasma metabolomics profiling of 580 patients from an Early Detection Research Network prostate cancer cohort
Abstract Prostate cancer is the second most common cancer in men and affects 1 in 9 men in the United States. Early screening for prostate cancer often involves monitoring levels of prostate-specific antigen (PSA) and performing digital rectal exams. However, a prostate biopsy is always required for...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2023-11-01
|
| Series: | Scientific Data |
| Online Access: | https://doi.org/10.1038/s41597-023-02750-7 |
| _version_ | 1797453971193856000 |
|---|---|
| author | Elisa Benedetti Kelsey Chetnik Thomas Flynn Christopher E. Barbieri Douglas S. Scherr Massimo Loda Jan Krumsiek |
| author_facet | Elisa Benedetti Kelsey Chetnik Thomas Flynn Christopher E. Barbieri Douglas S. Scherr Massimo Loda Jan Krumsiek |
| author_sort | Elisa Benedetti |
| collection | DOAJ |
| description | Abstract Prostate cancer is the second most common cancer in men and affects 1 in 9 men in the United States. Early screening for prostate cancer often involves monitoring levels of prostate-specific antigen (PSA) and performing digital rectal exams. However, a prostate biopsy is always required for definitive cancer diagnosis. The Early Detection Research Network (EDRN) is a consortium within the National Cancer Institute aimed at improving screening approaches and early detection of cancers. As part of this effort, the Weill Cornell EDRN Prostate Cancer has collected and biobanked specimens from men undergoing a prostate biopsy between 2008 and 2017. In this report, we describe blood metabolomics measurements for a subset of this population. The dataset includes detailed clinical and prospective records for 580 patients who underwent prostate biopsy, 287 of which were subsequentially diagnosed with prostate cancer, combined with profiling of 1,482 metabolites from plasma samples collected at the time of biopsy. We expect this dataset to provide a valuable resource for scientists investigating prostate cancer metabolism. |
| first_indexed | 2024-03-09T15:30:35Z |
| format | Article |
| id | doaj.art-d0a20e13995d4a0ca46dac4e068bf0ec |
| institution | Directory Open Access Journal |
| issn | 2052-4463 |
| language | English |
| last_indexed | 2024-03-09T15:30:35Z |
| publishDate | 2023-11-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Data |
| spelling | doaj.art-d0a20e13995d4a0ca46dac4e068bf0ec2023-11-26T12:18:16ZengNature PortfolioScientific Data2052-44632023-11-011011810.1038/s41597-023-02750-7Plasma metabolomics profiling of 580 patients from an Early Detection Research Network prostate cancer cohortElisa Benedetti0Kelsey Chetnik1Thomas Flynn2Christopher E. Barbieri3Douglas S. Scherr4Massimo Loda5Jan Krumsiek6Department of Physiology and Biophysics, Weill Cornell MedicineDepartment of Physiology and Biophysics, Weill Cornell MedicineDepartment of Urology, Weill Cornell Medical College, New York-Presbyterian HospitalDepartment of Urology, Weill Cornell Medical College, New York-Presbyterian HospitalDepartment of Urology, Weill Cornell Medical College, New York-Presbyterian HospitalDepartment of Pathology and Laboratory Medicine, Weill Cornell MedicineDepartment of Physiology and Biophysics, Weill Cornell MedicineAbstract Prostate cancer is the second most common cancer in men and affects 1 in 9 men in the United States. Early screening for prostate cancer often involves monitoring levels of prostate-specific antigen (PSA) and performing digital rectal exams. However, a prostate biopsy is always required for definitive cancer diagnosis. The Early Detection Research Network (EDRN) is a consortium within the National Cancer Institute aimed at improving screening approaches and early detection of cancers. As part of this effort, the Weill Cornell EDRN Prostate Cancer has collected and biobanked specimens from men undergoing a prostate biopsy between 2008 and 2017. In this report, we describe blood metabolomics measurements for a subset of this population. The dataset includes detailed clinical and prospective records for 580 patients who underwent prostate biopsy, 287 of which were subsequentially diagnosed with prostate cancer, combined with profiling of 1,482 metabolites from plasma samples collected at the time of biopsy. We expect this dataset to provide a valuable resource for scientists investigating prostate cancer metabolism.https://doi.org/10.1038/s41597-023-02750-7 |
| spellingShingle | Elisa Benedetti Kelsey Chetnik Thomas Flynn Christopher E. Barbieri Douglas S. Scherr Massimo Loda Jan Krumsiek Plasma metabolomics profiling of 580 patients from an Early Detection Research Network prostate cancer cohort Scientific Data |
| title | Plasma metabolomics profiling of 580 patients from an Early Detection Research Network prostate cancer cohort |
| title_full | Plasma metabolomics profiling of 580 patients from an Early Detection Research Network prostate cancer cohort |
| title_fullStr | Plasma metabolomics profiling of 580 patients from an Early Detection Research Network prostate cancer cohort |
| title_full_unstemmed | Plasma metabolomics profiling of 580 patients from an Early Detection Research Network prostate cancer cohort |
| title_short | Plasma metabolomics profiling of 580 patients from an Early Detection Research Network prostate cancer cohort |
| title_sort | plasma metabolomics profiling of 580 patients from an early detection research network prostate cancer cohort |
| url | https://doi.org/10.1038/s41597-023-02750-7 |
| work_keys_str_mv | AT elisabenedetti plasmametabolomicsprofilingof580patientsfromanearlydetectionresearchnetworkprostatecancercohort AT kelseychetnik plasmametabolomicsprofilingof580patientsfromanearlydetectionresearchnetworkprostatecancercohort AT thomasflynn plasmametabolomicsprofilingof580patientsfromanearlydetectionresearchnetworkprostatecancercohort AT christopherebarbieri plasmametabolomicsprofilingof580patientsfromanearlydetectionresearchnetworkprostatecancercohort AT douglassscherr plasmametabolomicsprofilingof580patientsfromanearlydetectionresearchnetworkprostatecancercohort AT massimoloda plasmametabolomicsprofilingof580patientsfromanearlydetectionresearchnetworkprostatecancercohort AT jankrumsiek plasmametabolomicsprofilingof580patientsfromanearlydetectionresearchnetworkprostatecancercohort |